Journey Medical Corporati... (DERM)
NASDAQ: DERM
· Real-Time Price · USD
6.92
-0.18 (-2.54%)
At close: May 16, 2025, 3:59 PM
6.93
0.22%
After-hours: May 16, 2025, 04:00 PM EDT
Journey Medical Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Accutane Revenue | 19.41M | 20.17M | 18.37M | 10.05M |
| Accutane Revenue Growth | -3.77% | +9.77% | +82.76% | n/a |
| Amzeeq Revenue | 5.01M | 6.2M | 7.24M | n/a |
| Amzeeq Revenue Growth | -19.22% | -14.37% | n/a | n/a |
| Qbrexza Revenue | 25.11M | 25.41M | 26.71M | n/a |
| Qbrexza Revenue Growth | -1.16% | -4.88% | n/a | n/a |
| Zilxi Revenue | 1.64M | 1.96M | 2.27M | n/a |
| Zilxi Revenue Growth | -16.26% | -13.68% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 10.57M | 10.06M | 11.4M | 10.33M | 8.42M | 9.84M | 8.64M | 12.14M | 13.29M | 13.99M | 15.57M | 15.19M | 14.71M | 15.06M | 10.76M | 7.79M | 6.23M | 5.82M | 5.83M | 4.75M | 5.22M | 46.36M | 63.33M | 48.68M | 52.68M | 49.51M | 40.77M | 31.64M | 27.24M | 148.31M | 13.59M | 11.33M | 9.49M | 8.28M | 6.37M | 5.9M | 7.44M | 4.68M | 3.85M | 4.15M |
| Selling, General, and Administrative Revenue Growth | +5.06% | -11.72% | +10.34% | +22.66% | -14.44% | +13.95% | -28.87% | -8.66% | -4.97% | -10.20% | +2.53% | +3.23% | -2.27% | +40.00% | +37.97% | +25.20% | +7.05% | -0.22% | +22.66% | -8.97% | -88.74% | -26.80% | +30.09% | -7.60% | +6.41% | +21.44% | +28.87% | +16.16% | -81.64% | +991.55% | +19.96% | +19.31% | +14.71% | +29.86% | +8.00% | -20.65% | +58.77% | +21.73% | -7.19% | n/a |
| Research and Development Revenue | 39K | 218K | 842K | 913K | 7.88M | 1.5M | 2.23M | 1.77M | 2.03M | 4.26M | 2.81M | 2.61M | 1.27M | 1.99M | 794K | 13.77M | n/a | n/a | n/a | n/a | n/a | 18.42M | 18.29M | 15.57M | 19.12M | 16.29M | 19.55M | 25.59M | 27.78M | 30.79M | 25.98M | 19.86M | 20.86M | 17.78M | 21.67M | 22.85M | 24.36M | 18.89M | 13.49M | 10.09M |
| Research and Development Revenue Growth | -82.11% | -74.11% | -7.78% | -88.42% | +423.85% | -32.48% | +25.65% | -12.74% | -52.23% | +51.35% | +7.78% | +106.08% | -36.45% | +150.88% | -94.23% | n/a | n/a | n/a | n/a | n/a | -100.00% | +0.72% | +17.44% | -18.57% | +17.35% | -16.64% | -23.63% | -7.89% | -9.76% | +18.52% | +30.81% | -4.79% | +17.30% | -17.93% | -5.19% | -6.17% | +28.95% | +39.98% | +33.77% | n/a |